6533b7ddfe1ef96bd1273fae
RESEARCH PRODUCT
Synthesis and In Vitro Evaluation of a Photosensitizer-BODIPY Derivative for Potential Photodynamic Therapy Applications
Mónica GorbeSalvador GilSalvador GilAna M. CosteroAna M. CosteroCristina De La TorreFélix SancenónJosé Ramón MurguíaRamón Martínez-máñezAndrea Barba-bonAndrea Barba-bonsubject
Boron CompoundsLightmedicine.medical_treatmentBodipyPhotodynamic therapyPhotochemistrysensorsBiochemistryHeLachemistry.chemical_compoundQUIMICA ORGANICACell Line TumormedicineBIOQUIMICA Y BIOLOGIA MOLECULARHumansPhotosensitizerchemistry.chemical_classificationReactive oxygen speciesPhotosensitizing AgentsphotochemistryMolecular StructureSinglet OxygenbiologySinglet oxygenEndoplasmic reticulumOrganic ChemistryQUIMICA INORGANICAGeneral Chemistrybiology.organism_classificationHaCaTPhotochemotherapychemistryphotodynamic therapyfluorescenceBODIPYReactive Oxygen Speciesdescription
A new photosensitizer (1) based on the 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY) scaffold has been synthesized. 1 is water soluble and showed an intense absorption band at 490 nm (e=77600 cm-1M-1) and an emission at 514 nm. In vitro toxicity of 1 in the presence of light and in darkness has been studied with HeLa, HaCaT, MCF-7, and SCC-13 cell lines. Moreover, internalization studies of 1 in these cell lines were also performed. These results suggested that 1 is more toxic for SCC-13 and HeLa carcinoma cells than for the HaCaT noncancerous immortal human keratinocytes. Toxicity upon light irradiation was due to the formation of singlet oxygen and reactive oxygen species (ROS). Cellular co-localization experiments revealed preferential localization of the dye in the endoplasmic reticulum.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2015-10-01 |